1. Executive Summary The pharmaceutical industry’s API manufacturing layer is undergoing a structural break, not an upgrade cycle. The convergence […]
A deep-dive for pharma IP teams, portfolio managers, and institutional investors on the strategies, IP valuations, and commercial mechanics that
Drug Patent Challenges: Win the Market, Not Just the Lawsuit Read Post »
The biopharma industry has spent decades optimizing for efficiency. Lean supply chains, single-source API relationships, centralized cell storage, and just-in-time
Biomedical Business Continuity: Build Resilience or Lose Market Share Read Post »
Own the Market After Your Patent Dies A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and
How to own a Market you Don’t Own: Market Access Strategies Post-Drug Patent Expiration Read Post »
Why Formulation Patents Are the Most Undervalued Asset in Pharma IP The pharmaceutical industry spent roughly $260 billion on R&D
For biopharma IP teams, portfolio managers, R&D leads, and institutional investors who track biologic patent cliffs for a living. 1.
Biosimilar Patent Strategy: The Complete IP, Litigation, and Market Entry Playbook Read Post »
Books and Research Papers Citing DrugPatentWatch All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 2025 — 11 Books and Research Papers Citing DrugPatentWatch Gregory, A. (2025).
How Academic Researchers and Policy Experts Use DrugPatentWatch Read Post »
A playbook for IP teams, portfolio managers, and R&D leads — from Paragraph IV mechanics and biosimilar patent dance tactics
The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated
Get fresh news and insights, drug patent expirations & more…
